Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

16-Gy low-voltage x-ray irradiation with ranibizumab therapy for AMD: 6-month safety and functional outcomes.

Canton VM, Quiroz-Mercado H, Velez-Montoya R, Lopez-Miranda MJ, Moshfeghi AA, Shusterman EM, Kaiser PK, Sanislo SR, Gertner M, Moshfeghi DM.

Ophthalmic Surg Lasers Imaging. 2011 Nov-Dec;42(6):468-73. doi: 10.3928/15428877-20110804-01. Epub 2011 Aug 11.

PMID:
21830747
2.

24-Gy low-voltage x-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes.

Canton VM, Quiroz-Mercado H, Velez-Montoya R, Lopez-Miranda MJ, Moshfeghi AA, Shusterman EM, Kaiser PK, Sanislo SR, Gertner M, Moshfeghi DM.

Ophthalmic Surg Lasers Imaging. 2012 Jan-Feb;43(1):20-4. doi: 10.3928/15428877-20111129-01.

PMID:
22251841
3.

16-Gy low-voltage x-ray irradiation followed by as-needed ranibizumab therapy for AMD: 6-month outcomes of a "radiation-first" strategy.

Moshfeghi AA, Canton VM, Quiroz-Mercado H, Velez-Montoya R, Lopez-Miranda MJ, Shusterman EM, Kaiser PK, Sanislo SR, Gertner M, Moshfeghi DM.

Ophthalmic Surg Lasers Imaging. 2011 Nov-Dec;42(6):460-7. doi: 10.3928/15428877-20110804-03. Epub 2011 Aug 11.

PMID:
21830745
4.

16 and 24 Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular age-related macular degeneration: 12-month outcomes.

Morales-Canton V, Quiroz-Mercado H, Velez-Montoya R, Zavala-Ayala A, Moshfeghi AA, Shusterman EM, Kaiser PK, Sanislo SR, Gertner M, Moshfeghi DM.

Am J Ophthalmol. 2013 Jun;155(6):1000-1008.e2. doi: 10.1016/j.ajo.2013.01.015. Epub 2013 Mar 14.

PMID:
23497847
5.

16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a 'radiation-first' strategy.

Moshfeghi AA, Morales-Canton V, Quiroz-Mercado H, Velez-Montoya R, Zavala-Ayala A, Shusterman EM, Kaiser PK, Sanislo SR, Gertner M, Moshfeghi DM.

Br J Ophthalmol. 2012 Oct;96(10):1320-4. Epub 2012 Aug 15.

PMID:
22895887
6.

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.

Brown DM, Chen E, Mariani A, Major JC Jr; SAVE Study Group.

Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.

PMID:
23131717
7.

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group.

Ophthalmology. 2013 May;120(5):1046-56. doi: 10.1016/j.ophtha.2012.10.014. Epub 2013 Jan 23.

8.

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M.

Am J Ophthalmol. 2007 Apr;143(4):566-83.

PMID:
17386270
9.

Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).

Dugel PU, Bebchuk JD, Nau J, Reichel E, Singer M, Barak A, Binder S, Jackson TL; CABERNET Study Group.

Ophthalmology. 2013 Feb;120(2):317-27. doi: 10.1016/j.ophtha.2012.07.068. Epub 2012 Nov 20.

PMID:
23174399
10.

Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.

Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N.

Retina. 2011 May;31(5):871-9. doi: 10.1097/IAE.0b013e3182003ca8.

PMID:
21358461
11.

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.

Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M.

Am J Ophthalmol. 2009 Jul;148(1):43-58.e1. doi: 10.1016/j.ajo.2009.01.024. Epub 2009 Apr 18.

PMID:
19376495
12.

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.

Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG.

Ophthalmology. 2009 Sep;116(9):1731-9. doi: 10.1016/j.ophtha.2009.05.024. Epub 2009 Jul 29.

PMID:
19643495
13.

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.

Spielberg L, Leys A.

Graefes Arch Clin Exp Ophthalmol. 2010 Jul;248(7):943-56. doi: 10.1007/s00417-009-1256-6. Epub 2010 Mar 4.

PMID:
20204659
14.

Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.

Jackson TL, Chakravarthy U, Kaiser PK, Slakter JS, Jan E, Bandello F, O'Shaughnessy D, Gertner ME, Danielson L, Moshfeghi DM; INTREPID Study Group.

Ophthalmology. 2013 Sep;120(9):1893-900. doi: 10.1016/j.ophtha.2013.02.016. Epub 2013 Mar 13.

PMID:
23490327
15.

Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.

Smailhodzic D, Muether PS, Chen J, Kwestro A, Zhang AY, Omar A, Van de Ven JP, Keunen JE, Kirchhof B, Hoyng CB, Klevering BJ, Koenekoop RK, Fauser S, den Hollander AI.

Ophthalmology. 2012 Nov;119(11):2304-11. doi: 10.1016/j.ophtha.2012.05.040. Epub 2012 Jul 26.

PMID:
22840423
16.

Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.

Dugel PU, Petrarca R, Bennett M, Barak A, Weinberger D, Nau J, Jackson TL.

Ophthalmology. 2012 Jul;119(7):1425-31. doi: 10.1016/j.ophtha.2012.01.014. Epub 2012 Mar 30.

PMID:
22465819
17.

One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections.

Arias L, Roman I, Masuet-Aumatell C, Rubio MJ, Caminal JM, Catala J, Pujol O.

Retina. 2011 Jul-Aug;31(7):1261-7. doi: 10.1097/IAE.0b013e318207d152.

PMID:
21499194
18.

Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.

Jackson TL, Dugel PU, Bebchuk JD, Smith KR, Petrarca R, Slakter JS, Jaffe GJ, Nau JA; CABERNET Study Group.

Ophthalmology. 2013 Aug;120(8):1597-603. doi: 10.1016/j.ophtha.2013.01.074. Epub 2013 Mar 13.

PMID:
23490325
19.

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N.

Ophthalmology. 2006 Apr;113(4):633.e1-4. Epub 2006 Feb 14.

PMID:
16483659
20.

Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.

Gupta B, Adewoyin T, Patel SK, Sivaprasad S.

Br J Ophthalmol. 2011 Mar;95(3):386-90. doi: 10.1136/bjo.2010.179499. Epub 2010 Aug 6.

PMID:
20693484

Supplemental Content

Support Center